Pharmacokinetic Analysis of Ziyuglycoside Ⅰ in Normal and Acute Kidney Injury Rats
10.13422/j.cnki.syfjx.20250163
- VernacularTitle:地榆皂苷Ⅰ在正常和急性肾损伤大鼠体内的药代动力学分析
- Author:
Yunhui ZHANG
1
;
Yanli LIU
2
;
Qiongming XU
2
;
Shuding SUN
1
;
Hongjin ZHU
1
;
Di ZHAO
1
;
Suxiang FENG
1
Author Information
1. Henan University of Chinese Medicine，Zhengzhou 450046，China
2. Soochow University，Suzhou 215000，China
- Publication Type:Journal Article
- Keywords:
ziyuglycoside Ⅰ;
acute kidney injury;
cisplatin;
ultra-high performance liquid chromatography-quadrupole-electrostatic field orbital trap-linear ion-trap mass spectrometry（UPLC-Orbitrap Fusion Lumos Tribrid-MS）;
plasma concentration;
pharmacokinetics
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(5):203-210
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveBased on ultra-high performance liquid chromatography-quadrupole-electrostatic field orbital trap-linear ion-trap mass spectrometry（UPLC-Orbitrap Fusion Lumos Tribrid-MS）， the plasma concentration of ziyuglycoside Ⅰ was determined at different time points after oral administration， and its pharmacokinetic characteristics in normal rats and rats with acute kidney injury were compared. MethodsRats were randomly divided into normal group and model group， the model group received intraperitoneal cisplatin（10 mg·kg-1） to establish the acute kidney injury model， the normal group was given the same volume of saline. After successful modeling， rats in the normal and model groups were randomly divided into the normal low， medium and high dose groups（2.5， 5， 7.5 mg·kg-1） and the model low， medium and high dose groups（2.5， 5， 7.5 mg·kg-1）， 6 rats in each group， and the plasma was collected at different time points after receiving the corresponding dose of ziyuglycoside Ⅰ. Then， the concentration of ziyuglycoside Ⅰ in rat plasma was determined by UPLC-Orbitrap Fusion Lumos Tribrid-MS， and the drug-time curve was poltted. The pharmacokinetic parameters were calculated by Kinetica 5.1 software， and the differences in pharmacokinetic parameters between different administration groups were compared by independent sample t-test with SPSS 22.0. ResultsThe pharmacokinetic results showed that after receiving the different doses of ziyuglycoside Ⅰ， its concentration increased first and then decreased， and all of them reached the maximum plasma concentration at about 0.5 h. The area under the curve（AUC0-t） and mean retention time（MRT0-t） of normal and model rats increased with the increased dose， and the clearance（CL） decreased with the increasing dose. Compared with the normal group， the AUC0-t was significantly increased（P<0.01）， peak concentration（Cmax） and CL decreased in model rats at different doses， indicating that the physiological state of the rats could affect the absorption and elimination of ziyuglycoside Ⅰ in vivo. ConclusionThe pharmacokinetic characteristics of ziyuglycoside Ⅰ are quite different in normal rats and acute kidney injury model rats， which may be due to the change of the body environment in the pathological state， then lead to changes in absorption and metabolic processes.
